# PyrAmes

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pyrames

- Industry: Medical Devices & Equipment
- Headquarters: US
- Website: www.pyrameshealth.com
- Total disclosed funding: $6M
- Latest round: Series A (Apr 20, 2021)
- Investors on record: 3

## About

PyrAmes, Inc. is a digital health company specializing in innovative non-invasive blood pressure monitoring solutions, enhancing patient care through its advanced monitoring platforms tailored for various patient demographics.PyrAmes, Inc. focuses on digital health solutions, specifically continuous non-invasive blood pressure monitoring. The company was founded by Xina Quan, who is also the CEO. PyrAmes, headquartered in the US, raised USD 6.000 mn in Series A funding on April 20, 2021, led by GSR Ventures with participation from Keytone Ventures and XTX Ventures. This funding supports the company’s growth initiatives.PyrAmes Inc. specializes in digital health solutions, focusing primarily on continuous non-invasive blood pressure monitoring (cNIBP) through its innovative platforms, including Boppli®, Bosimi®, and Bosimi@Home™. The Boppli® platform is specifically designed for neonatal and pediatric patients, providing accurate, real-time blood pressure monitoring without the need for invasive arterial lines or cumbersome cuff-based methods, thus enhancing patient comfort and safety. The Bosimi® platform caters to adult inpatient and emergency care settings, while Bosimi@Home™ addresses diagnostic and treatment validation for home medical management. PyrAmes’ products serve a diverse clientele, including hospitals, neonatal intensive care units, and healthcare providers across various geographical markets such as the United States and Canada, aiming to improve blood pressure management for patients of all ages.PyrAmes generates revenue primarily through the sales of its FDA-cleared medical devices, including its flagship product, Boppli®. The company's transaction structure involves direct sales to hospitals and healthcare facilities that purchase the devices outright or enter into partnerships for ongoing supply and support. PyrAmes also engages in business-to-business (B2B) transactions, where healthcare providers incorporate the technology into their clinical practice to enhance patient care. Revenue streams are further supported by potential subscription models related to the software and data analytics components of its platforms, enabling continuous monitoring and health management solutions.PyrAmes plans to use the USD 6.000 mn raised in Series A funding to accelerate the commercialization of its novel products through pilot-scale manufacturing, clinical validation studies, and regulatory agency reviews. The company is focused on launching new products that enhance non-invasive monitoring capabilities in the coming years. PyrAmes is also targeting expansion into additional markets across North America and beyond, with specific plans to establish a presence in Europe by 2023.

## Funding rounds

- Series A, Apr 20, 2021, $6M — GSR Ventures, Keytone Ventures, XTX Ventures

## Investors

- GSR Ventures (https://capitalatlas.ai/funds/gsr-ventures) — Series A
- Keytone Ventures (https://capitalatlas.ai/funds/keytone-ventures) — Series A
- XTX Ventures (https://capitalatlas.ai/funds/xtx-ventures) — Series A